questionsmedicales.fr
États, signes et symptômes pathologiques
Signes et symptômes
Signes et symptômes digestifs
Hyperphagie
Hyperphagie : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Hyperphagie : Questions médicales les plus fréquentes",
"headline": "Hyperphagie : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Hyperphagie : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-28",
"dateModified": "2025-02-22",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Hyperphagie"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Signes et symptômes digestifs",
"url": "https://questionsmedicales.fr/mesh/D012817",
"about": {
"@type": "MedicalCondition",
"name": "Signes et symptômes digestifs",
"code": {
"@type": "MedicalCode",
"code": "D012817",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C23.888.821"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Boulimie",
"alternateName": "Bulimia",
"url": "https://questionsmedicales.fr/mesh/D002032",
"about": {
"@type": "MedicalCondition",
"name": "Boulimie",
"code": {
"@type": "MedicalCode",
"code": "D002032",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C23.888.821.645.500"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Hyperphagie",
"alternateName": "Hyperphagia",
"code": {
"@type": "MedicalCode",
"code": "D006963",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Andrea M Haqq",
"url": "https://questionsmedicales.fr/author/Andrea%20M%20Haqq",
"affiliation": {
"@type": "Organization",
"name": "Department of Pediatrics, University of Alberta, 8440 - 112 St NW, Edmonton, AB, T6G 2B7, Canada. haqq@ualberta.ca."
}
},
{
"@type": "Person",
"name": "Arashdeep Singh",
"url": "https://questionsmedicales.fr/author/Arashdeep%20Singh",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacodynamics, Center for Integrative Cardiovascular and Metabolic Disease, University of Florida, Gainesville, FL, USA."
}
},
{
"@type": "Person",
"name": "Julia von Schnurbein",
"url": "https://questionsmedicales.fr/author/Julia%20von%20Schnurbein",
"affiliation": {
"@type": "Organization",
"name": "Center for Rare Endocrine Diseases, Division of Paediatric Endocrinology and Diabetes, Department of Paediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm, Germany."
}
},
{
"@type": "Person",
"name": "Martin Wabitsch",
"url": "https://questionsmedicales.fr/author/Martin%20Wabitsch",
"affiliation": {
"@type": "Organization",
"name": "Center for Rare Endocrine Diseases, Division of Paediatric Endocrinology and Diabetes, Department of Paediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm, Germany. Electronic address: Martin.Wabitsch@uniklinik-ulm.de."
}
},
{
"@type": "Person",
"name": "Usha G Mallya",
"url": "https://questionsmedicales.fr/author/Usha%20G%20Mallya",
"affiliation": {
"@type": "Organization",
"name": "Rhythm Pharmaceuticals, Inc., Boston, MA, USA."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Pathological survey of precursor lesions in cholangiocarcinoma.",
"datePublished": "2023-02-18",
"url": "https://questionsmedicales.fr/article/36707055",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/jhbp.1308"
}
},
{
"@type": "ScholarlyArticle",
"name": "Prognostic factors in patients with intrahepatic cholangiocarcinoma.",
"datePublished": "2024-08-17",
"url": "https://questionsmedicales.fr/article/39154139",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-024-70124-z"
}
},
{
"@type": "ScholarlyArticle",
"name": "Expression and molecular insights of lima1 in cholangiocarcinoma.",
"datePublished": "2024-07-30",
"url": "https://questionsmedicales.fr/article/39076043",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/19336918.2024.2383068"
}
},
{
"@type": "ScholarlyArticle",
"name": "Effect of age on the prognosis of intrahepatic cholangiocarcinoma.",
"datePublished": "2022-12-21",
"url": "https://questionsmedicales.fr/article/36541019",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3904/kjim.2022.146"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cholangiocarcinoma: Epidemiology and Imaging-Based Review.",
"datePublished": "2024-05-02",
"url": "https://questionsmedicales.fr/article/38687269",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": null
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "États, signes et symptômes pathologiques",
"item": "https://questionsmedicales.fr/mesh/D013568"
},
{
"@type": "ListItem",
"position": 3,
"name": "Signes et symptômes",
"item": "https://questionsmedicales.fr/mesh/D012816"
},
{
"@type": "ListItem",
"position": 4,
"name": "Signes et symptômes digestifs",
"item": "https://questionsmedicales.fr/mesh/D012817"
},
{
"@type": "ListItem",
"position": 5,
"name": "Hyperphagie",
"item": "https://questionsmedicales.fr/mesh/D006963"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Hyperphagie - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Hyperphagie",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-15",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Hyperphagie",
"description": "Comment diagnostiquer l'hyperphagie ?\nQuels tests sont utilisés pour l'hyperphagie ?\nL'hyperphagie est-elle liée à d'autres troubles ?\nQuels critères DSM sont utilisés pour l'hyperphagie ?\nL'hyperphagie peut-elle être confondue avec d'autres troubles ?",
"url": "https://questionsmedicales.fr/mesh/D006963?mesh_terms=Cholangiocarcinoma&page=4#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Hyperphagie",
"description": "Quels sont les symptômes de l'hyperphagie ?\nL'hyperphagie provoque-t-elle des douleurs ?\nY a-t-il des signes psychologiques associés ?\nComment l'hyperphagie affecte-t-elle le poids ?\nL'hyperphagie peut-elle causer des troubles métaboliques ?",
"url": "https://questionsmedicales.fr/mesh/D006963?mesh_terms=Cholangiocarcinoma&page=4#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Hyperphagie",
"description": "Comment prévenir l'hyperphagie ?\nLe soutien social aide-t-il à prévenir l'hyperphagie ?\nLes programmes de sensibilisation sont-ils efficaces ?\nL'exercice physique aide-t-il à prévenir l'hyperphagie ?\nLes techniques de relaxation sont-elles utiles ?",
"url": "https://questionsmedicales.fr/mesh/D006963?mesh_terms=Cholangiocarcinoma&page=4#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Hyperphagie",
"description": "Quels traitements sont disponibles pour l'hyperphagie ?\nLa thérapie cognitive est-elle efficace ?\nDes médicaments sont-ils prescrits pour l'hyperphagie ?\nLe soutien nutritionnel est-il important ?\nL'hyperphagie nécessite-t-elle une hospitalisation ?",
"url": "https://questionsmedicales.fr/mesh/D006963?mesh_terms=Cholangiocarcinoma&page=4#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Hyperphagie",
"description": "Quelles complications peuvent survenir avec l'hyperphagie ?\nL'hyperphagie peut-elle affecter la santé mentale ?\nY a-t-il des risques de maladies cardiovasculaires ?\nDes problèmes digestifs peuvent-ils survenir ?\nL'hyperphagie peut-elle entraîner des troubles du sommeil ?",
"url": "https://questionsmedicales.fr/mesh/D006963?mesh_terms=Cholangiocarcinoma&page=4#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Hyperphagie",
"description": "Quels sont les facteurs de risque de l'hyperphagie ?\nLe stress est-il un facteur de risque ?\nLes antécédents de troubles alimentaires augmentent-ils le risque ?\nL'isolement social est-il un facteur de risque ?\nLes changements hormonaux influencent-ils l'hyperphagie ?",
"url": "https://questionsmedicales.fr/mesh/D006963?mesh_terms=Cholangiocarcinoma&page=4#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer l'hyperphagie ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'évaluation des habitudes alimentaires et des symptômes associés."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour l'hyperphagie ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Aucun test spécifique, mais des évaluations psychologiques et nutritionnelles peuvent être effectuées."
}
},
{
"@type": "Question",
"name": "L'hyperphagie est-elle liée à d'autres troubles ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut coexister avec des troubles comme l'anxiété ou la dépression."
}
},
{
"@type": "Question",
"name": "Quels critères DSM sont utilisés pour l'hyperphagie ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le DSM-5 définit des critères spécifiques pour le trouble de l'hyperphagie boulimique."
}
},
{
"@type": "Question",
"name": "L'hyperphagie peut-elle être confondue avec d'autres troubles ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut être confondue avec la boulimie ou l'orthorexie."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes de l'hyperphagie ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent une consommation excessive de nourriture, des sentiments de honte et de culpabilité."
}
},
{
"@type": "Question",
"name": "L'hyperphagie provoque-t-elle des douleurs ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut entraîner des douleurs abdominales dues à une suralimentation fréquente."
}
},
{
"@type": "Question",
"name": "Y a-t-il des signes psychologiques associés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des signes comme l'anxiété, la dépression et une faible estime de soi sont fréquents."
}
},
{
"@type": "Question",
"name": "Comment l'hyperphagie affecte-t-elle le poids ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut entraîner une prise de poids significative et des problèmes de santé associés."
}
},
{
"@type": "Question",
"name": "L'hyperphagie peut-elle causer des troubles métaboliques ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut contribuer à des troubles métaboliques comme le diabète de type 2."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'hyperphagie ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention passe par une éducation nutritionnelle et la gestion du stress."
}
},
{
"@type": "Question",
"name": "Le soutien social aide-t-il à prévenir l'hyperphagie ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un bon soutien social peut réduire le risque de développer des troubles alimentaires."
}
},
{
"@type": "Question",
"name": "Les programmes de sensibilisation sont-ils efficaces ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les programmes de sensibilisation peuvent aider à identifier et à traiter les problèmes tôt."
}
},
{
"@type": "Question",
"name": "L'exercice physique aide-t-il à prévenir l'hyperphagie ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier peut améliorer l'humeur et réduire les comportements alimentaires compulsifs."
}
},
{
"@type": "Question",
"name": "Les techniques de relaxation sont-elles utiles ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des techniques comme la méditation peuvent aider à gérer le stress et les envies alimentaires."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour l'hyperphagie ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent la thérapie comportementale, la médication et le soutien nutritionnel."
}
},
{
"@type": "Question",
"name": "La thérapie cognitive est-elle efficace ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la thérapie cognitive peut aider à modifier les comportements alimentaires et les pensées."
}
},
{
"@type": "Question",
"name": "Des médicaments sont-ils prescrits pour l'hyperphagie ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antidépresseurs et des médicaments anti-anxiété peuvent être prescrits pour aider."
}
},
{
"@type": "Question",
"name": "Le soutien nutritionnel est-il important ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un soutien nutritionnel aide à établir des habitudes alimentaires saines."
}
},
{
"@type": "Question",
"name": "L'hyperphagie nécessite-t-elle une hospitalisation ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Dans les cas graves, une hospitalisation peut être nécessaire pour un traitement intensif."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec l'hyperphagie ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent l'obésité, le diabète, et des problèmes cardiovasculaires."
}
},
{
"@type": "Question",
"name": "L'hyperphagie peut-elle affecter la santé mentale ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut aggraver des troubles mentaux comme la dépression et l'anxiété."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de maladies cardiovasculaires ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'hyperphagie augmente le risque de maladies cardiovasculaires en raison de l'obésité."
}
},
{
"@type": "Question",
"name": "Des problèmes digestifs peuvent-ils survenir ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des problèmes comme le reflux gastro-œsophagien et des douleurs abdominales peuvent se produire."
}
},
{
"@type": "Question",
"name": "L'hyperphagie peut-elle entraîner des troubles du sommeil ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut causer des troubles du sommeil en raison de l'inconfort physique et psychologique."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque de l'hyperphagie ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux, des troubles mentaux et des événements stressants."
}
},
{
"@type": "Question",
"name": "Le stress est-il un facteur de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress émotionnel peut déclencher des épisodes d'hyperphagie chez certaines personnes."
}
},
{
"@type": "Question",
"name": "Les antécédents de troubles alimentaires augmentent-ils le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, avoir des antécédents de troubles alimentaires augmente le risque d'hyperphagie."
}
},
{
"@type": "Question",
"name": "L'isolement social est-il un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'isolement social peut contribuer à des comportements alimentaires désordonnés."
}
},
{
"@type": "Question",
"name": "Les changements hormonaux influencent-ils l'hyperphagie ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des changements hormonaux, comme ceux liés à la grossesse, peuvent affecter l'appétit."
}
}
]
}
]
}
To clarify the pathological significance of two precursors (high-grade biliary intraepithelial neoplasm [BilIN] and intraductal papillary neoplasm of bile duct [IPNB]) in cholangiocarcinomas (CCAs)....
Ninety-one cases of CCA (47 distal CCAs [dCCAs], 31 perihilar CCAs [pCCAs] and 13 intrahepatic CCAs of large duct type [LD-iCCAs]) were examined for their association with precursors. Neoplastic intra...
Fifty-four and 8 of 91 CCAs were associated with high-grade BilIN and IPNB, respectively, while these precursors were unidentifiable in the remaining CCAs. A majority of CCAs were of the gastrobiliary...
CCAs were frequently associated with precursors; high-grade BilIN may be a major precursor and IPNB a minor one. CCAs with IPNB showed a favorable postoperative OS compared to CCAs with high-grade Bil...
Intrahepatic cholangiocarcinoma (ICC) is the second commonly-seen liver malignancy and one of the most fatal cancers in Taiwan. Survival after diagnosis of ICC remains poor. This study aimed to invest...
Lim Domain and Actin Binding protein1 (lima1) influence cancer cell function. Thus far, functional role of lima1 in cholangiocarcinoma remains unknown. We used public databases, in vitro experiments, ...
Intrahepatic cholangiocarcinoma (iCCA) is a subgroup of cholangiocarcinoma and is the second- most-common primary hepatic tumor. Several predictive and prognostic factors have been analyzed; however, ...
A retrospective analysis of patients treated between 2005 and 2016 at Konkuk University Medical Center. In total, 133 patients with iCCA were identified. The mass-forming, periductal-infiltrating, and...
In total, 114 patients were enrolled. The two groups differed with regard to treatment options such as surgery with adjuvant chemotherapy or palliative chemotherapy (p = 0.012, p < 0.001). The younger...
Younger patients and those who underwent surgery with adjuvant chemotherapy had longer survival. The younger the patient, the more treatments received, including palliative chemotherapy....
Cholangiocarcinoma (CCA) is a rare cancer of the bile duct epithelium, and in the last few decades its incidence rate has been increasing. It is associated with a high mortality rate due to late diagn...
Hilar cholangiocarcinoma is considered a biologically aggressive disease for which surgical resection remains the only curative treatment. Preoperative evaluation for resectability is challenging give...
The survival rate of patients with irresectable perihilar cholangiocarcinoma is remarkably poor. An essential part of palliation is treatment of obstructive cholestasis caused by the tumor. Currently,...
Between 2005 and 2016, we treated 120 pCCC patients with primary palliative care. Three treatment strategies were retrospectively considered: extrahepatic bile duct resection (EBR), exploratory laparo...
The EBR group required significantly less stenting postoperatively, and the overall morbidity was 29.4% (EBR). After the surgical procedure, fewer subsequent endoscopic treatments for stenting or PTBD...
In selected pCCC patients, palliative extrahepatic bile duct resection is a feasible option for treatment of obstructive cholestasis and should be reconsidered as a therapy option for these patients e...
Intrahepatic cholangiocarcinoma (ICC) is a malignant tumor, which poses a serious threat to human health. Histone 3 lysine 9 trimethylation (H3K9me3) is a post-translational modification involved in r...
In this study, we applied the ChIP-seq technique to investigate the effect of H3K9me3 on ICC. Anti-H3K9me3 antibody was used for ChIP-seq in ICC (RBE cell lines) and HIBEpic (normal cell lines). MACS2...
H3K9me3 exhibited abnormal methylation and influenced the process of abnormal gene expression in patients suffering from ICC. The Wnt/β-Catenin signaling pathway (also known as simply the WNT signalin...
We are the first to report that H3K9me3 may play an important role in the progression of ICC. It promotes the understanding of epigenetic molecular mechanisms for ICC....
Cholangiocarcinoma (CCA) is a group of malignancies of the bile ducts with high mortality rates and limited treatment options. In the past decades, remarkable efforts have been dedicated toward elucid...
Cholangiocarcinoma is a rare tumor but a challenging cancer in terms of pathological changes, clinical manifestations and therapeutic options. Recent studies have provided evidence for participation o...